Shenzhen Hepalink Pharmaceutical Gets US Distribution License for Anticonvulsant Drug

MT NewswiresJan 3 16:18

Hepalink Partners With Yongtai for U.S. Gabapentin Market

TipRanksJan 2 16:37

HEPALINK (09989.HK) signed a distribution agreement with Yongtai Pharmaceutical.

On January 2, Gelonghui reported that HEPALINK (09989.HK) announced it had signed a distribution agreement with Zhejiang Yongtai Pharmaceutical Co., Ltd. ("Yongtai Pharmaceutical") on December 31, 2024, whereby Yongtai Pharmaceutical grants the company the license to commercialize Gabapentin capsules ("symbol pharmaceutical") throughout the USA. According to the agreement, the company will purchase the symbol pharmaceutical from Yongtai Pharmaceutical at an agreed price and will be responsible for the commercialization of the symbol pharmaceutical in the USA. Apart from the symbol pharmaceutical supply price explicitly stated in the agreement, the company is not required to pay any other fees to Yongtai Pharmaceutical.

Gelonghui FinanceJan 2 16:33

Express News | HEPALINK: Signed a distribution agreement with Yungtay Pharmaceutical to obtain commercialization license for Gabapentin capsules in the USA.

BreakingsJan 2 16:26

How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.

On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.

Zhitong FinanceDec 30, 2024 13:32

Express News | State Council meeting: Deploy measures to deepen the reform of Pharmaceutical and medical instruments regulatory system to promote high-quality development of the pharmaceutical industry.

BreakingsDec 24, 2024 19:10